Instructions for Authors 2019

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Conflicts of Interest; (h) Authors’ contributions; (i) Acknowledgements; (j) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html

In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iiar@iiar-anticancer.org) within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:

- The Instructions to Authors must be followed in every detail.
- The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
- The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
- Results given in figures should not be repeated in tables.
- Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
- Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
- Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
- Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
- Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
- The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
- By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:

- they do not fall within the journal's policy.
- they do not follow the instructions for authors.
- language is unclear.
- results are not sufficient to support a final conclusion.
- results are not objectively based on valid experiments.
- they repeat results already published by the same or other authors before the submission to AR.
- plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2019 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterisation of models of biomedical research.

The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance (3 months from submission).

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

ISSN (online): 1791-7549

Selection of Recent Articles


A Simple and Easily Reproducible Model of Reversible Obstructive Jaundice in Rats. S. HIRATANI, R. MORI, Y. OTA, R. MATSUYAMA, T. KUMAMOTO, Y. NAGASHIMA, D. MORIOKA, I. ENDO (Yokohama, Japan)


Reconstruction of Spinal Soft Tissue Deficits With Perforator Flaps From the Paraspinal Region. P.G. DI SUMMA, R.D. LARGO, T. ISMAIL, M. TREMP, A. LUNGER, R. WETTSTEIN, S.M. KRÄHENBÜHL, S. GIORDANO, D.F. KALBERMATTEN, D.J. SCHAEFER, F.M. THIERINGER (Basel; Allschwil, Switzerland; Turku, Finland)


Mid- to Long-term Outcomes After Split-thickness Skin Graft vs. Skin Extension by Multiple Incisions. J.N. KERN, F. WEIDEMANN, P.F. O’LOUGHLIN, C. KRETTEK, R. GAULKE (Hanover, Germany; Cork, Ireland)


Fistein Suppresses Human Osteosarcoma U-2 OS Cell Migration and Invasion via Affecting FAK, p130CAK and NF-kB Signaling Pathway In Vitro. J.-K. CHUNG (Changhua; Taichung; Tainan; Yilan, Taiwan, ROC)

Definitive Radiotherapy for Older Patients Aged ≥75 Years With Localized Esophageal Cancer. G. SUZUKI, H. YAMADA, N. ABE, K. MASUI, T. KIMOTO, D. SHIMIZU, T. NISHIMURA, A. NAKASHIMA, K. MACHIDA, K. KAWABATA, Y. OTA, H. FUJWARA, T. ISHIKAWA, K. YAMADA (Kyoto, Japan)
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors. J. GIULIANI, A. BONETTI (Legnago, Italy) ................................................................. 3961

The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil. J. GIULIANI, A. BONETTI (Legnago, Italy) ................. 3967

The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab. J. GIULIANI, A. BONETTI (Legnago, Italy) ................................................................. 3971

Errata ........................................................................................................................................................................ 3975

Book Reviews ............................................................................................................................................................. 3977

Announcements ............................................................................................................................................................ 3979
Clinical Characteristics Associated With Lenvatinib-induced Fistula and Tumor-related Bleeding in Patients With Thyroid Cancer. Y. STAUB, A. NISHIYAMA, Y. SUGA, M. FUJITA, R. MATSUSHITA, S. YANO (Kanazawa, Japan) .......................................................................................................................... 3871

Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents. N. YAMAGUCHI, S. MORIZANE, T. YUMIOKA, H. IWAMOTO, K. HIKITA, T. SEJIMA, M. HONDA, A. TAKENAKA (Yonago; Matsue, Japan) .................................................................................. 3879


Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies. K. FUJITA, N. UCHIDA, Y. YAMAMOTO, O. KANAI, M. OKAMURA, K. NAKATANI, S. SAWAI, T. MIO (Kyoto, Japan) ........................................................................................................................................ 3917


S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. T. ITO, Y. HONMA, H. HIRANO, H. SHOJI, N. OKITA, S. IWASA, A. TAKASHIMA, K. KATO, N. BOKU (Tokyo, Japan) ........................................................................................................................................ 3931

Random Allocated Study of Wrapping Oblate for Prevention of Everolimus-associated Stomatitis in Patients With Metastatic Renal Cell Carcinoma. K. PARK, Y. BAEK, J.-L. LEE (Gyeongsangnam-do; Seoul, Republic of Korea) ........................................................................................................................................ 3937

Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma. A. MARJANSKA, P. GALAŻKA, M. MARIJANSKI, M. WYSOCKI, J. STYCZYNSKI (Bydgoszcz, Poland) .......................................................................................................................... 3945


Panniculitis Under Successful Targeted Inhibition of the MAPK/ERK Signaling Pathway in a Patient With BRAF V600E-mutated Spindle Cell Oncocytoma of the Pituitary Gland. L. SOLLFRANK, S. LETTMAYER, M. ERDMANN, U. USLU (Erlangen, Germany) ........................................................................................................................................ 3955

Contents continued on the preceding page
Resveratrol Modulates the Redox-status and Cytotoxicity of Anticancer Drugs by Sensitizing Leukemic Lymphocytes and Protecting Normal Lymphocytes. D. IVANOVA, Z. ZHELEV, S. SEMKOVA, I. AOKI, R. BAKALOVA (Stara Zagora; Sofia, Bulgaria; Chiba, Japan) ................................................................. 3745

Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition. J.Y. KIM, Y.J. PARK, B.-M. LEE, S. YOON (Suwon, Republic of Korea) ................................................................. 3757

Histamine Receptor Antagonists, Loratadine and Azelastine, Sensitize P-gp-overexpressing Antimitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms. J.Y. KIM, K.S. KIM, I.S. KIM, S. YOON (Suwon, Republic of Korea) ................................................................. 3767

Selenoesters and Selenoanhydrides as Novel Agents Against Resistant Breast Cancer. A. CSONKA, A. KINCSES, M. NOVÉ, Z. VADAS, C. SANMARTÍN, E. DOMÍNGUEZ-ÁLVAREZ, G. SPENGLER (Szeged, Hungary; Pamplona; Madrid, Spain) ................................................................. 3777

Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp. J.Y. KIM, H.S. KIM, S. YOON (Suwon, Republic of Korea) ................................................................. 3785

In Vitro Evaluation of Apoptotic Induction of Butyric Acid Derivatives in Colorectal Carcinoma Cells. L. PATTAYIL, H.-T. BALAKRISHNAN-SARASWATHI (Kerala, India) ................................................................. 3795

AXL Downstream Targeting Unravels Synergistic Drug Combinations in Ovarian Carcinoma Cells. D.M. ALAMPI, E. CIUSANI, N. CARENINI, E. CORNA, L. GATTI, C. CORNO (Milan, Italy) ................................................................. 3803


In Vivo Effectiveness of Orlistat in the Suppression of Human Colorectal Cancer Cell Proliferation. A. CZUMAJ, J. ZABIELSKA, A. PAKIET, A. MIKA, O. ROSTKOWSKA, W. MAKAREWICZ, J. KOBIELA, T. SLEDZINSKI, E. STELMANSKA (Gdansk, Poland) .................................................. 3815

Virtual Screening of 1,4-Naphthoquinone Derivatives for Inhibition of a Key Cancer Signaling Protein, AKT1 Kinase. M. REHAN, M. MOSTAFA (Jeddah, Kingdom of Saudi Arabia; Cairo, Egypt) ................................................................. 3823

Lupane Triterpenoids and New Derivatives as Antiproliferative Agents Against Prostate Cancer Cells. M.J. CASTRO, V.P. CAREAGA, P.A. SACCA, M.B. FARAONI, A.P. MURRAY, J.C. CALVO (Bahía Blanca; Buenos Aires, Argentina) ................................................................. 3835

Clinical Studies

Marking Disappearing Colorectal Liver Metastases After Complete Response to Neoadjuvant Chemotherapy via CT – A Pilot Study. J. VUJIC, H. SCHÖLLNAST, K. MARSONER, V. WIENERROITHER, H. BACHER, H.-J. MISCHINGER, P. KORNPRAT (Graz, Austria) ................................................................. 3847

Follow-up Results of HCV GT2 Patients After Sofosbuvir/Ribavirin Therapy: Careful Attention to Occurrence of HCC. T. KANEKO, T. ISHIKAWA, A. SHIBATA, A. TAMURA, M. OGAWA, N. NAKAJIMA, S. MATSUOKA, K. URODA, T. KOMORIYA, T. TAMAMOTO, T. TAKAYAMA, M. MORIYAMA (Tokyo; Chiba, Japan) ................................................................. 3855

Matrix-producing Carcinoma as an Aggressive Triple-negative Breast Cancer: Clinicopathological Features and Response to Neoadjuvant Chemotherapy. K. SHIMADA, T. ISHIKAWA, A. YAMADA, S. SUGAE, K. NARUI, D. SHIMIZU, T. CHISHIMA, I. ENDO (Yokohama; Chigasaki; Tokyo, Japan) ................................................................. 3863

Contents continued on the preceding page
Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells. G. LI PETRI, S. CASCIOFERRO, B. EL HASSOUNI, D. CARBONE, B. PARRINO, G. CIRRINCIONE, G.J. PETERS, P. DIANA, E. GIOVANNETTI (Palermo; Pisa, Italy; Amsterdam, the Netherlands) .......................... 3615

Cetrimonium Bromide Inhibits Cell Migration and Invasion of Human Hepatic SK-HEP-1 Cells Through Modulating the Canonical and Non-canonical TGF-β Signaling Pathways. T.-K. WU, C.-H. CHEN, Y.-R. PAN, C.-W. HU, F.-M. HUANG, J.-Y. LIU, C.-J. LEE (Taichung; Miaoli; Changhua, Taiwan, ROC) ......................... 3621

DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines. V. LANDGRAF, M. GRIESSMANN, J. ROLLER, C. POLEDNIK, M. SCHMIDT (Wuerzburg, Germany) ............ 3633


Inhibition of Pancreatic Carcinoma Growth Through Enhancing ω-3 Epoxy Polyunsaturated Fatty Acid Profile by Inhibition of Soluble Epoxide Hydrolase. R. XIA, L. SUN, J. LIAO, H. LI, X. YOU, D. XU, J. YANG, S.H. HWANG, R.D. JONES, B. HAMMOCK, G.-Y. YANG (Chicago, IL; Davis, CA, USA) 3651

Selective Wnt/β-catenin Small-molecule Inhibitor CWP232228 Impairs Tumor Growth of Colon Cancer. J.Y. KIM, G. PARK, M. KRISHNAN, E. HA, K.-S. CHUN (Daegu, Republic of Korea) ........................................ 3661

Suppression of ERK/NF-κB Activation Is Associated With Amentoflavone-Inhibited Osteosarcoma Progression In Vivo. Y.-J. LEE, J.-G. CHUNG, Y.-T. CHIEN, S.-S. LIN, F.-T. HSU (Kaohsiung; Taichung, Taiwan, ROC) .................................................. 3669


Autophagy Promotes Survival of CHP-212 Neuroblastoma Cells Treated With Casiopeinas®. A. VÁZQUEZ-AGUIRE, A.G. GUTIÉRREZ, R.M. ESPARZA, E. HERNÁNDEZ-LEMUS, L. RUIZ-AZUARA, C. MEJÍA (Querétaro; Jalapa; Mexico City, Mexico) .......................................................... 3687

The Ethanol Crude Extraction of Cyperus Rotundus Regulates Apoptosis-associated Gene Expression in HeLa Human Cervical Carcinoma Cells In Vitro. C.-H. LIN, S.-F. PENG, F.-S. CHUEH, Z.-Y. CHENG, C.-L. KUO, J.-G. CHUNG (Taichung, Taiwan, ROC) .................................................. 3697


Interleukin-24 Transduction Modulates Human Prostate Cancer Malignancy Mediated by Regulation of Anchorage Dependence. S. MAEHANA, Y. MATSUMOTO, F. KOJIMA, H. KITASATO (Kanagawa, Japan) ........................................ 3719

Combination of Vaccine Strain Measles Virus and Nimotuzumab in the Treatment of Laryngeal Cancer. N.L. TOAN, N.T. HANG, N.K. LUU, C.V. MAO, N.V. BA, N.T. XUAN, T.D. CAM, N. YAMAMOTO, H.V. TONG, H.A. SON (Hanoi; Ho Chi Minh, Vietnam; Singapore, Singapore) ........................................................................ 3727


Contents continued on the preceding page
Natural and Synthetic Isothiocyanates Possess Anticancer Potential Against Liver and Prostate Cancer In Vitro. E. CROWLEY, N.J. ROWAN, D. FALLER, A.M. FRIEL (Athlone, Ireland) .................................................. 3469

Acyclic Retinoid Combined With Tenascin-C-derived Peptide Reduces the Malignant Phenotype of Neuroblastoma Cells Through N-Myc Degradation. K. OTSUKA, M. SASADA, Y. HIRANO, Y. NOHARA, T. IYODA, Y. HIGAMI, H. KODAMA, F. FUKAI (Noda; Sanyo-Onoda; Saga, Japan) .................................................. 3487

IL-29 Exhibits Anti-Tumor Effect on Pan-48 Pancreatic Cancer Cells by Up-regulation of P21 and Bax. D. BALABANOV, L. ZHAO, Z. ZHU, Z.E. HUNZEKER, H.M. TONNER, V.A. DING, M.R. WAKEFIELD, Q. BAI, Y. FANG (Des Moines, IA; Columbia, MO, USA; Hefei, PR China) .................................................................................. 3493


Induction of Non-Apoptotic Cell Death by Adrenergic Agonists in Human Oral Squamous Cell Carcinoma Cell Lines. S. UCHIDA, K. KOBAYASHI, S. OHNO, H. Sakagami, H. KOHASE, H. NAGASAKA (Saitama; Moroyama, Japan) ................................................................................................................................ 3519

Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells. P. WIŃSKA, Ł. WIDŁO, K. SKIERKA, A. KRZYŚKO, M. KORONKIEWICZ, J.M. CIEŚŁA, J. CIEŚŁA, M. BRETNER (Warsaw, Poland) .................................................................................................................. 3531

Bevacizumab Versus Anti-preeclamptic Drugs: Evaluation With Three-dimensionally Co-cultured Human Mini Tumors. C. PAN, K. ONDA, T. HIRANO (Tokyo, Japan; Beijing, PR China) ........................................................................................................ 3543

Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines. J. IWASAKI, T. KOMORI, F. NAKAGAWA, H. NAGASE, J. UCHIDA, K. MATSUO, Y. UTO (Tokushima; Tsukuba, Japan) ................................................................................................................................ 3553

ChIP-seq Analysis to Explore DNA Replication Profile in Trifluridinetreated Human Colorectal Cancer Cells In Vitro. T. KOBUNAI, K. MATSUOKA, T. TAKECHI (Tokyo; Tokushima, Japan) ........................................................................................................ 3565

Down-regulation of Survivin by BIX-01294 Pretreatment Overcomes Resistance of Hepatocellular Carcinoma Cells to TRAIL. Y. NAMGUNG, S.Y. KIM, I. KIM (Seoul, Republic of Korea) ........................................................................................................ 3571

Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines. K. HAGIWARA, T. TOKUNAGA, H. IIDA, H. NAGAI (Nagoya, Japan) ................................................................................................................................ 3579

Broad-spectrum Cross-resistance to Anticancer Drugs Mediated by Epidermal Growth Factor Receptor. G. YAN, T. EFFERTH (Mainz, Germany) ........................................................................................................ 3585

Perampanel Inhibits Neuroblastoma Cell Proliferation Through Down-regulation of AKT and ERK Pathways. A. NOZAWA, M. OZEKI, M. MATSUOKA, M. NAKAMA, S. YASUE, S. ENDO, N. KAWAMOTO, H. OHNISHI, T. FUKAO (Gifu, Japan) ........................................................................................................ 3595

The Involvement of Pregnanex X Receptor-regulated Pathways in the Antitumor Activity of Cisplatin. M. YASUDA, S. KISHIMOTO, M. AMANO, S. FUKUSHIMA (Kobe, Japan) ................................................................................................................................ 3601

Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. B. EL HASSOUNI, J. INFANTE, G. MANTINI, C. RICCI, N. FUNEL, E. GIOVANNETTI, G.J. PETERS (Amsterdam, the Netherlands; Pisa, Italy) ................................................................................................................................ 3609

Contents continued on the preceding page
Potential Molecular Mechanisms of the Anti-cancer Activity of Vitamin D. D. SKRAJNOWSKA, B. BOBROWSKA-KORCZAK (Warsaw, Poland) ................................................................. 3353

Therapy Aimed to Suppress the Production of the Immunosuppressive Protein Progesterone Induced Blocking Factor (PIBF) May Provide Palliation and/or Increased Longevity for Patients With a Variety of Different Advanced Cancers – A Review. J.H. CHECK, D. CHECK (Camden; Mt. Laurel, NJ, USA) .......................... 3365

Glucans as New Anticancer Agents. P. SIMA, J. RICHTER, V. VETVICKA (Prague; Ústí nad Labem, Czech Republic; Louisville, KY, USA) .......................................................... 3373

Inhibitors of Protein Tyrosine Phosphatase PTP1B With Anticancer Potential. T. KOSTRZEWA, J. STYSZKO, M. GORSKA-PONIKOWSKA, T. SLEDZINSKI, A. KUBAN-JANKOWSKA (Gdansk, Poland) .......................................................... 3379

Acyl-Coenzyme A: Cholesterol Acyltransferase Inhibition in Cancer Treatment. J. ZABIELSKA, T. SLEDZINSKI, E. STELMANSKA (Gdansk, Poland) ................................................. 3385

Extracellular Vesicles: Subcellular Organelles With the Potential to Spread Cancer Resistance. F. ENDER, N. VON BUBNOFF, F. GIESELER (Luebeck, Germany) ................................. 3395

State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now? R. BALSANO, C. TOMMASI, I. GARAJOVA (Parma, Italy) .......................................................... 3405

A Brief Guide to Performing Pharmacological Studies In Vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacology”. M. CAPULA, C. CORNO, B. EL HASSOUNI, G. LI PETRI, S. ARANDELOVIĆ (Pisa; Milan; Palermo, Italy; Amsterdam, the Netherlands; Belgrade, Serbia) .............. 3413

Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. A. RODALLEC, R. FANCIUILLINO, S. BENZEKRY, J. CICCOLINI (Marseille; Bordeaux, France; Brussels, Belgium).................................................................. 3419

Pleiotropic Chemotherapy to Abrogate Glioblastoma Multiforme Migration/Invasion. L. HELSON, M. MAJEED (East Windsor, NJ, USA) ......................................................... 3423

In Vitro Anticancer Activities of B6 Vitamers: A Mini-review. T. MATSUO, Y. SADZUKA (Iwate, Japan) .......................................................... 3429

Experimental Studies

Biochemical Inhibition of DOG1/TMEM16A Achieves Antitumoral Effects in Human Gastrointestinal Stromal Tumor Cells In Vitro. R. FRÖBOM, F. SELLBERG, C. XU, A. ZHAO, C. LARSSON, W.-O. LUI, I.-L. NILSSON, E. BERGLUND, R. BRÄNSTRÖM (Stockholm; Uppsala, Sweden) .......................................................... 3433

Oxidative DNA Damage and Apoptosis Induced by Aclarubicin, an Anthracycline: Role of Hydrogen Peroxide and Copper. H. MIZUTANI, Y. HAYASHI, M. HASHIMOTO, M. IMAI, Y. CHIMARU, Y. KITAMURA, K. IKEMURA, D. MIYAZAWA, K. OHTA, Y. IKEDA, T. MAEDA, M. YOSHIIKAWA, Y. HIRAKU, S. KAWANISHI (Nagoya; Tsu; Eiheiji; Suzuka, Japan) .......................................................... 3443

Unravelling the Antioproliferative Activity of 1,2,5-oxadiazole Derivatives. D. EHRSAM, F. PORTA, M. MORI, H.É. MEYER ZU SCHWABEDISSEN, L. DALLA VIA, A.N. GARCIA-ARGAEZ, L. BASILE, F. MENEGHETTI, S. VILLA, A. GELAIN (Basel, Switzerland; Milan; Padua; Catania, Italy) ........................................................................................................ 3453


Contents continued on the preceding page